Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy.
Zarubova Jana J, Hasani-Sadrabadi Mohammad Mahdi MM, Wu Yutong Y, Diamante Graciel G et al.
Embryonic development is characterized by remarkable immune tolerance, yet whether this property extends to pluripotent stem cell-derived extracellular vesicles (EVs) has remained unclear. Here we show that EVs from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells, outperform mesenchymal stem cell-derived EVs in suppressing proinflammatory cytokine secretion, reducing T cell activation and inducing regulatory T cells. PSC EVs display distinct molecular signatures, containing unique proteins and microRNAs absent from mesenchymal stem cell-derived EVs, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family. Dynamic suspension culture of PSC aggregates enhances the EV yield, providing a scalable and reproducible source. Delivered via a biomaterial scaffold, two local injections of induced PSC EVs significantly improved diabetes-free survival in an antigen-specific type 1 diabetes model, increasing regulatory T cell populations in draining lymph nodes, as well as inducing systemic immune modulation and preserving β-cell mass. These findings establish PSC EVs as a scalable immunomodulatory platform for autoimmune disease and for immune tolerance in cell therapy.